Asset Details
Do you wish to reserve the book?
Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
Do you wish to request the book?
Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)
2025
Overview
Background Zervimesine (CT1812) is an experimental oral, small‐molecule drug candidate in development for Alzheimer’s disease and dementia with Lewy bodies (DLB). Zervimesine is designed to protect neurons by preventing the binding of oligomers of pathogenic proteins including β‐amyloid and ɑ‐synuclein. Method The COG1201 ‘SHIMMER’ study is the first study to measure tolerability and clinical effects of zervimesine in adults with DLB. The study enrolled 130 individuals with a clinical diagnosis of DLB and MMSE of 18‐27 who were randomized 1:1:1 to receive once‐daily oral doses of zervimesine (100 or 300 mg) or placebo for 26 weeks. Among clinical assessments tools, SHIMMER employed the Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study‐Activities of Daily Living (ADCS‐ADL) scale and the Unified Parkinson's Disease Rating Scale (UPDRS) Part III. Result Zervimesine‐treated participants experience strong therapeutic responses across behavioral, functional, cognitive, and movement measures in SHIMMER. At the end of the study period, zervimesine‐treated DLB (n=88) patients progressed 86% slower than placebo‐treated patients (n=42) on the NPI, 52% slower on the ADCS‐ADL and 62% slower on the UPDRS Part III. We intend to present for the first time a detailed characterization of the baseline participant characteristics including demographics, baseline scores on outcome measures, concomitant medications, comorbidities and baseline biomarker levels. Conclusion These data will allow comparison of the SHIMMER population to prior DLB study populations. SHIMMER results support the potential for zervimesine to slow clinical progression in patients with mild‐to‐moderate DLB. The robust therapeutic response observed across neuropsychiatric, cognitive, motor and functional measures is particularly encouraging. An analysis of participant characteristics will help guide recruitment in future clinical studies of zervimesine and its potential use to treat people with DLB. Cognition Therapeutics conducted COG1201 with University of Miami Miller School of Medicine and the Lewy Body Dementia Association under a grant from the National Institute of Aging (R01AG071643).
